BackTable Urology
Ep. 193 Bladder Cancer Innovations: ESMO 2024 Highlights with Dr. Andrea Apolo
Dr. Andrea Apolo
So great question. I think the standard of care has been the standard of care for a while until we had the approval of nivolumab in the adjuvant setting. And that just happened. It wasn't that long ago. 2021 was when that occurred. And I think that what I would have done differently had I known the activity of nivolumab and the activity of pembrolizumab.
0
💬
0
Comments
Log in to comment.
There are no comments yet.